Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;35:655-661

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Komers, R.
Right arrow Articles by Anderson, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Komers, R.
Right arrow Articles by Anderson, S.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Animal models of human disease
Right arrow Hypertension - basic studies
Right arrow Endothelium/vascular type/nitric oxide

(Hypertension. 2000;35:655.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Effects of Systemic Inhibition of Neuronal Nitric Oxide Synthase in Diabetic Rats

Radko Komers; Terry T. Oyama; Justin G. Chapman; Kristen M. Allison; Sharon Anderson

From the Division of Nephrology and Hypertension, Oregon Health Sciences University, and Portland VA Medical Center, Portland, Ore.

Abstract—Diabetes is associated with alterations in nitric oxide–mediated vasomotor function. The role of nitric oxide generated via the neuronal nitric oxide synthase pathway in the control of systemic and renal hemodynamics in diabetes has not been studied. To explore the hypothesis that diabetic vascular dysfunction is in part caused by altered neuronal nitric oxide synthase activity, systemic and renal hemodynamics were assessed before and after acute inhibition of this enzyme with a specific inhibitor, S-methyl-L-thiocitrulline, in control and diabetic rats. The interaction of this pathway and the renin-angiotensin system was studied in separate groups of rats pretreated with the angiotensin II receptor blocker losartan; these rats were compared with rats treated with losartan alone. Diabetic animals demonstrated higher baseline glomerular filtration rates and filtration fractions. At a low dose, the neuronal nitric oxide synthase inhibitor induced similar dose-dependent pressor responses in control and diabetic rats. Losartan abolished the pressor response in both groups. No changes in renal plasma flow or renal vascular resistance occurred in control rats. In contrast, diabetic rats responded with significant renal vasoconstriction. At a high dose, the renal vasoconstriction was similar in both groups and was not affected by losartan. In conclusion, neuronal nitric oxide synthase–derived nitric oxide plays a role in the control of systemic and renal hemodynamics in normal and diabetic rats. Diabetic rats are more sensitive to the inhibitor, suggesting increased activity of this pathway in the diabetic kidney. Furthermore, renal responses in diabetic rats were attenuated by angiotensin II receptor blockade, whereas losartan alone induced hemodynamic changes that were opposite those seen with neuronal nitric oxide synthase inhibition. This observation implicates angiotensin II as an important modulator of this nitric oxide pathway in diabetes.


Key Words: blood pressure • diabetes • S-methyl-L-thiocitrulline • nitric oxide • nitric oxide synthase




This article has been cited by other articles:


Home page
DiabetesHome page
M. L. Onozato, A. Tojo, J. Leiper, T. Fujita, F. Palm, and C. S. Wilcox
Expression of NG,NG-Dimethylarginine Dimethylaminohydrolase and Protein Arginine N-Methyltransferase Isoforms in Diabetic Rat Kidney: Effects of Angiotensin II Receptor Blockers
Diabetes, January 1, 2008; 57(1): 172 - 180.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
N. Toda, K. Ayajiki, and T. Okamura
Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation
Pharmacol. Rev., March 1, 2007; 59(1): 54 - 87.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. Z. Levine, M. Iacovitti, S. J. Robertson, and G. A. Mokhtar
Modulation of single-nephron GFR in the db/db mouse model of type 2 diabetes mellitus
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2006; 290(4): R975 - R981.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
K. R. Tuttle, M. E. Puhlman, S. K. Cooney, and R. A. Short
Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes
Am J Physiol Renal Physiol, January 1, 2002; 282(1): F103 - F112.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. Cervenka, H. J. Kramer, J. Maly, and J. Heller
Role of nNOS in Regulation of Renal Function in Angiotensin II-Induced Hypertension
Hypertension, August 1, 2001; 38(2): 280 - 285.
[Abstract] [Full Text] [PDF]